So what’s star Broad in­ves­ti­ga­tor Feng Zhang up to now?

Ac­cord­ing to an SEC fil­ing from a few days ago, star Broad in­ves­ti­ga­tor Feng Zhang and a group of high-pro­file sci­en­tists and in­vestors have formed a new biotech called Ar­bor Biotech­nolo­gies and raised $12.2 mil­lion of a $15.6 mil­lion of­fer­ing.

Full cred­it: Reuters briefed the news June 1 and the Boston Busi­ness Jour­nal made the con­nec­tion with the sci­en­tist ear­li­er to­day.

Zhang, you will re­mem­ber, pro­vid­ed much of the orig­i­nal in­sight and IP that went in­to the CRISPR/Cas9 tech in use at Ed­i­tas $ED­IT, one of a group of gene edit­ing ri­vals in that has been duk­ing it out to be the first in the clin­ic with a pi­o­neer­ing hu­man study. That ri­val­ry in­cludes an in­tense dis­pute over the patents the Broad ob­tained. Ed­i­tas has al­so gone on to build its patent port­fo­lio and Zhang has been hard at work search­ing for new and bet­ter ways to do gene edit­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER